FdaApplication
NDA 021798
Identifiers
- fda_app_no: NDA021798
Properties
| Property | Value |
|---|---|
| applicant_name | BRISTOL MYERS SQUIBB |
| application_type | NDA |
| approval_date | 2005-03-29 |
Revenue by product
BARACLUDE
| Period | Revenue |
|---|---|
| Q3 2021 | $105.0M |
| Q2 2021 | $109.0M |
| Q1 2021 | $113.0M |
| Q4 2020 | $104.0M |
| Q3 2020 | $100.0M |
| Q2 2020 | $121.0M |
| Q1 2020 | $122.0M |
| Q4 2019 | $122.0M |
| Q3 2019 | $145.0M |
| Q2 2019 | $147.0M |
| Q1 2019 | $141.0M |
| Q4 2018 | $165.0M |
| Q3 2018 | $175.0M |
| Q2 2018 | $179.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| BARACLUDE | ENTECAVIR | 0.05MG/ML | SOLUTION;ORAL |
1 product